<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109212</url>
  </required_header>
  <id_info>
    <org_study_id>004SC06084</org_study_id>
    <secondary_id>2006-006191-38</secondary_id>
    <nct_id>NCT01109212</nct_id>
  </id_info>
  <brief_title>The Effects of Bindarit in Diabetic Nephropathy</brief_title>
  <official_title>The Effects of the Association Bindarit + Irbesartan Versus Irbesartan Alone on Albuminuria on Patients With Diabetic Nephropathy. Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether bindarit is effective to reduce
      albuminuria, compared to placebo, in nephropathic patients treated with irbesartan, as a
      background therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot phase II, double-blind, multicentre, randomized, placebo-controlled, parallel
      groups study in patients with DN undergoing irbesartan therapy.

      According to screening urinary albumin excretion, at baseline and before randomization, all
      patients will be categorized into 2 strata:

      Stratum 1: microalbuminuria (20 to 200 μg/min, in at least 2 of 3 consecutive overnight urine
      samples collected at the screening) Stratum 2: macroalbuminuria (&gt;200 μg/min, in at least 2
      of 3 consecutive overnight urine samples collected at the screening).

      Within each stratum, patients will be randomly allocated on a 1:1 basis to the 2 treatment
      arms (after one month induction period):

        -  bindarit 600MG twice a day

        -  placebo All patients will be treated with irbesartan 300 mg/day as background therapy.
           After 12 months of treatment albuminuria will be evaluated as primary endopoint.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Albumin Excretion (µg/min) levels in the overnight urine specimen.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Relative change (per cent change) in Urinary Albumin Excretion (UAE) from the baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Monocyte Chemoattractant protein (MCP-1/CCL2)(pg/ml) levels in the overnight urine specimen.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Relative change (per cent change) in Urinary MCP-1 levels from the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipids</measure>
    <time_frame>12 weeks</time_frame>
    <description>Relative change (per cent change) in total cholesterol, cholesterol HDL, triglycerides, apolipoprotein-A, apolipoprotein-B from the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of bindarit in association of irbesartan.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in anthropometrics, laboratory parameters and vital signs from the baseline. Number of adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria remission rates</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rate of remission from macro to microalbuminuria and from micro to normoalbuminuria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Bindarit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with bindarit 2x300 mg bid plus irbesartan 2x150 mg once a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients treated with placebo 2 tablets bid plus irbesartan 2x150 mg once a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bindarit</intervention_name>
    <description>dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks</description>
    <arm_group_label>Bindarit</arm_group_label>
    <other_name>AF2838</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  male and female patients with no limitation of race, aged 30 to 70 years;

          -  Type 2 diabetes defined as: &gt; 30 years of age at diagnosis; insulin not required
             within 6 months of initial diagnosis; no history of diabetic ketoacidosis; currently
             treated with diet, oral hypoglycemics or insulin [Brenner 2000];

          -  microalbuminuria defined as urinary albumin excretion, 20 to 200 µg/min in at least 2
             of 3 overnight urine samples or macroalbuminuria defined as urinary albumin excretion,
             &gt; 200 µg/min in at least 2 of 3 overnight urine samples, confirmed in the baseline
             collection; should baseline albuminuria data not to be available, the patient may be
             conditionally treated;

          -  glycosylated haemoglobin (Hb A1c) &lt;12% at Screening [Brenner 2000];

          -  serum creatinine ≤ 3 mg/dL at Screening;

          -  normotensive patients or hypertensive patients on stable antihypertensive therapy over
             the last 3 months and without specific contraindications to angiotensin antagonist
             therapy;

          -  female patients of childbearing potential required to have a negative pregnancy test
             and use an approved birth control method;

          -  patients legally able to give written informed consent to the trial (signed and dated
             by the patient).

        EXCLUSION CRITERIA

        Patients cannot enter the trial under the following circumstances:

          -  patients hypersensitive or allergic to ARBs or bindarit or its components, or with a
             positive history for drug allergy;

          -  Type 1 diabetes [Brenner 2000];

          -  history of non diabetic renal disease, including renal artery stenosis [Brenner 2000];

          -  history of heart failure before enrolment [Brenner 2000];

          -  acute myocardial infarction, coronary artery bypass grafting within the past one month
             [Brenner 2000];

          -  cerebral vascular accident or coronary angioplasty within the past six months month
             [Brenner 2000];

          -  Transient Ischemic Attacks (TIA) in the past 12 months [Brenner 2000];

          -  primary aldosteronism or pheocromocytoma [Brenner 2000];

          -  severe uncontrolled hypertension (sitting diastolic blood pressure &gt; 115 and/or
             sitting systolic blood pressure&gt; 220 mm Hg) in the previous 6 months;

          -  chronic use of corticosteroids, non-steroidal anti-inflammatory drugs,
             immunosuppressive drugs, MAO inhibitors;

          -  patients under the influence of alcohol or narcotics;

          -  patients treated with experimental drugs in the previous 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Remuzzi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mario Negri Institute for Pharmacological Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Mario Negri Institute for Pharmacological Research- Clinical Research Center for Rare Diseases</name>
      <address>
        <city>Ranica</city>
        <state>Bergamo</state>
        <zip>24020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Treviglio-Caravaggio - Unità Operativa Malattie Metaboliche e Diabetologia</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera OO.RR. Bergamo - Unità Operativa Diabetologia</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione Centro S. Raffaele del Monte Tabor- Unità Operativa Medicina Generale</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ist. Patologia Medica e metodologia Clinica - Università di Sassari</name>
      <address>
        <city>Sassari</city>
        <zip>7100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Dpt Endocrinology Diabetes and Metabolic Diseases- Diabetology Unit</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Slovenia</country>
  </location_countries>
  <link>
    <url>http://www.angelinipharma.com</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2-Diabetic Nephrophaty</keyword>
  <keyword>bindarit</keyword>
  <keyword>albuminuria</keyword>
  <keyword>MCP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

